Influvac Tetra: clinical experience on safety, efficacy, and immunogenicity

Area of Science:

• Vaccinology
• Immunology
• Public Health

Background:

• Seasonal influenza is a significant vaccine-preventable disease with potential for severe complications.
• Various influenza vaccines exist, including egg-based, cell-based, and recombinant types, with ongoing innovation like mRNA vaccines.
• Despite available vaccines, influenza vaccination coverage remains below recommended levels, particularly in at-risk groups and healthcare workers.

Purpose of the Study:

• To summarize safety and immunogenicity data for Influvac Tetra from its clinical development program.
• To present findings across all age groups, starting from six months of age.

Main Methods:

• The study is based on five registration studies for Influvac Tetra.
• Studies included diverse age groups, comparators, and participants from Europe and Asia.
• Safety and immunogenicity were evaluated in all studies; efficacy was assessed in one study.

Main Results:

• Influvac Tetra demonstrated safety and immunogenicity across all evaluated age groups.
• Data were collected during the vaccine's clinical development program.

Conclusions:

• Influvac Tetra is a safe and immunogenic option for seasonal influenza prevention in individuals aged six months and older.
• The findings support the use of Influvac Tetra in clinical practice to improve influenza vaccination coverage.